Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 20, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	273	265	74	1,050	890	278
Market Cap Growth	76.38%	256.84%	-92.92%	17.97%	220.59%	254.99%
Enterprise Value	102	95	-110	805	650	238
Last Close Price	2.46	2.48	1.05	15.75	14.54	6.47
PS Ratio	18.09	14.18	2.38	35.30	131.67	42.84
PB Ratio	2.22	1.71	0.47	5.32	4.51	7.38
P/TBV Ratio	2.22	1.71	0.47	5.51	4.68	9.10
EV/Sales Ratio	6.45	5.06	-	27.04	96.09	36.79
Debt / Equity Ratio	0.02	0.02	0.02	0.01	0.02	0.38
Asset Turnover	0.09	0.09	0.14	0.12	0.04	0.08
Quick Ratio	3.93	3.88	3.86	9.94	8.38	3.69
Current Ratio	3.93	3.99	4.16	10.56	8.94	3.87
Return on Equity (ROE)	-113.23%	-84.46%	-49.88%	-44.01%	-77.33%	-95.12%
Return on Assets (ROA)	-22.98%	-15.72%	-31.67%	-21.04%	-25.38%	-35.87%
Return on Capital (ROIC)	-32.23%	-20.59%	-39.70%	-26.60%	-32.43%	-48.16%
Return on Capital Employed (ROCE)	-43.90%	-27.80%	-68.80%	-36.60%	-28.60%	-86.80%
Earnings Yield	-53.16%	-49.76%	-118.96%	-8.28%	-10.21%	-18.37%
FCF Yield	-16.14%	-7.61%	-107.07%	-6.49%	-5.89%	-14.08%
Buyback Yield / Dilution	-62.68%	-10.73%	-7.05%	-14.95%	-33.36%	-2.94%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q